Outcome of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Genetic Features

Documenti analoghi

• Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
  di: Stephens, Deborah M., et al.
  Pubblicazione: (2012)
• Reduced Occurrence of Tumor Flare with Flavopiridol Followed by Combined Flavopiridol and Lenalidomidein Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
  di: Maddocks, Kami, et al.
  Pubblicazione: (2015)
• Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
  di: Rogers, Kerry A., et al.
  Pubblicazione: (2018)
• Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
  di: Lin, Thomas S., et al.
  Pubblicazione: (2009)
• Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
  di: Stephens, Deborah M., et al.
  Pubblicazione: (2014)